The innovative drug sector is experiencing a confluence of positive catalysts in 2026, signaling a clear industry recovery. On the policy front, the government work report for the first time categorized biopharmaceuticals as an emerging pillar industry, with more supportive measures expected. Industrially, business development (BD) transactions remain robust; in January-February alone, the total value of outbound BD deals for Chinese innovative drugs surpassed $50 billion, nearing 40% of the previous full year's total. From a market perspective, following a correction since October 2025, the sector's valuation is currently at a cyclical low, with increasing certainty for a rebound.
Amid this improving industry climate, BIOCYTOGEN-B (02315.HK, 688796.SH) reported impressive financial results. After achieving its first profit in 2024, the company realized scaled profitability in 2025. Full-year revenue reached 1.379 billion yuan, a year-on-year increase of 40.63%. Net profit attributable to shareholders surged by 416.37% to 173 million yuan, while non-GAAP net profit grew by 405.39% to 116 million yuan. The gross profit margin remained stable at 75.83%, and operating cash flow reached 370 million yuan. These figures indicate the company has transitioned beyond the early R&D investment phase into a harvest period of sustained profit elasticity.
While the strong financial data acts as a short-term catalyst for the stock price, the more significant development is the shift in the company's valuation logic. Unlike being merely a model animal supplier or a preclinical CRO, BIOCYTOGEN-B has evolved into a platform biotechnology company with a comprehensive innovative technology moat by building an integrated technology system encompassing model animals, antibody development, and preclinical CRO services.
Focusing on essential needs in new drug R&D, the company's true value is accelerating. Among global experimental animal models, mice are the most commonly used due to their high genomic homology with humans. However, developing target-humanized mice involves multiple rounds of gene editing, presenting challenges such as high technical difficulty, long R&D cycles, and scarce suppliers. In the gene editing field, BIOCYTOGEN-B has established a competitive edge through deep technological expertise. Its complete toolkit, ranging from ESC/HR and CRISPR/EGE to its self-developed SUPCE technology, and from routine gene editing to megabase-scale large fragment modification, supports high-throughput, high-complexity model development.
To date, the company has developed over 5,000 proprietary gene-edited mouse models, including more than 2,000 target-humanized mouse strains. This creates a globally leading "off-the-shelf" supply capability, reducing the average industry delivery time for animal models from 12-24 months to just weeks, significantly enhancing R&D efficiency for global pharmaceutical companies. In 2025, its model animal business generated revenue of 622 million yuan, up nearly 60% year-on-year, with a gross margin exceeding 80%, providing stable cash flow.
Extending further down the value chain, BIOCYTOGEN-B's target-humanized mice and preclinical CRO business form a "product + service" closed loop. Clients selecting mice can subsequently commission the company for pharmacodynamic evaluation, saving transportation time and improving experimental efficiency. In 2025, the preclinical CRO business revenue reached 352 million yuan, a 75.24% increase, with over 8,600 drug evaluation projects completed cumulatively and a high client retention rate of 80%, indicating a sticky customer base.
If model animals and CRO services are the foundational support for new drug R&D, then BIOCYTOGEN-B's "RenMab" program and its underlying antibody development business represent the high-value segment of the innovative drug industry chain. The "RenMab" initiative has conducted large-scale immunization for over 1,000 targets, creating a repository of more than one million authentic antibody sequences. This allows new drug developers to bypass lengthy custom immunization processes and directly select pre-validated, high-quality candidate molecules from this "antibody shelf," potentially shortening R&D cycles by 1-2 years. BIOCYTOGEN-B maximizes the value of this technology through various models, including antibody licensing and collaborative development. In 2025, the antibody development business revenue was 332 million yuan with an 86% gross margin. The company has signed over 350 cooperation agreements cumulatively, including more than 150 new agreements in 2025 alone. Nearly 70% of its annual revenue came from overseas, with service networks covering the US, Europe, and Asia-Pacific markets. Its partners include global leaders such as Merck KGaA, Gilead, Johnson & Johnson, and BeiGene, demonstrating strong international recognition of its technological capabilities.
Looking further ahead, BIOCYTOGEN-B's strategic moves in artificial intelligence (AI) present a new long-term growth driver. Leveraging the massive real-world data accumulated from the "RenMab" program, the company has built RenSuper Workstation, reportedly the world's first real-data-driven intelligent platform. This system utilizes AI to analyze antibody sequences for structure, epitope, and functional potential, integrating the discovery, evaluation, and decision-making for lead antibody molecules into a unified process. This makes the identification of lead antibodies more efficient, reliable, and translatable. In the future, the platform is expected to support multi-dimensional conditional searches and comparisons, rapidly identifying experimentally validated candidate sequences, and facilitating the design of various molecular formats like bispecific, trispecific, and multi-specific antibodies. The company has completed the local deployment of the AI platform and initial construction of an automation platform. This strategic layout not only promises to accelerate R&D efficiency across existing businesses but also further solidifies the company's technological moat.
In summary, on one hand, two consecutive years of profitability and positive operating cash flow confirm the company's earning capability, providing a solid safety margin for its valuation. On the other hand, its integrated platform of antibody development, model animals, and preclinical CRO services is rapidly maturing. As the market's valuation logic for the company gradually shifts, a repricing is likely. With short-term performance catalysts driving the stock price and long-term value becoming increasingly apparent, BIOCYTOGEN-B, supported by its innovative technology, unique business model, and favorable position within the global new drug R&D ecosystem, is well-positioned to be a primary beneficiary of the industry's recovery.
Comments